Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control
- 26 May 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 45 (12), 1925-1931
- https://doi.org/10.1016/j.jacc.2005.03.041
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetesDiabetic Medicine, 2004
- Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetesAmerican Heart Journal, 2004
- Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinedionesThrombosis and Haemostasis, 2004
- Carotid Intima-Media Thickness Measurements in Intervention StudiesStroke, 2003
- Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat ModelLaboratory Investigation, 2003
- Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic PatientsCirculation, 2003
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Metformin, but not Thiazolidinediones, Inhibits Plasminogen Activator Inhibitor-1 Production in Human Adipose Tissuein VitroHormone and Metabolic Research, 2003
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPARγ in Endothelial FunctionBiochemical and Biophysical Research Communications, 1999